KR20250174932A - 혈우병 a를 가지는 대상의 처치를 위한, 활성화 응고 제ix 인자 및 응고 제x 인자와 결합하는 이중 특이성 항체와 혈액 응고 제x 인자의 병용 - Google Patents

혈우병 a를 가지는 대상의 처치를 위한, 활성화 응고 제ix 인자 및 응고 제x 인자와 결합하는 이중 특이성 항체와 혈액 응고 제x 인자의 병용

Info

Publication number
KR20250174932A
KR20250174932A KR1020257037065A KR20257037065A KR20250174932A KR 20250174932 A KR20250174932 A KR 20250174932A KR 1020257037065 A KR1020257037065 A KR 1020257037065A KR 20257037065 A KR20257037065 A KR 20257037065A KR 20250174932 A KR20250174932 A KR 20250174932A
Authority
KR
South Korea
Prior art keywords
factor
hemophilia
bispecific antibody
antibody
fixa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257037065A
Other languages
English (en)
Korean (ko)
Inventor
케이지 노가미
유토 나카지마
카즈키 시미즈
에이스케 타카미
히로토시 나카노
Original Assignee
고리츠다이가쿠호징 나라켕리츠 이카다이가쿠
케이엠 바이올로직스 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고리츠다이가쿠호징 나라켕리츠 이카다이가쿠, 케이엠 바이올로직스 가부시키가이샤 filed Critical 고리츠다이가쿠호징 나라켕리츠 이카다이가쿠
Publication of KR20250174932A publication Critical patent/KR20250174932A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020257037065A 2023-04-28 2024-04-26 혈우병 a를 가지는 대상의 처치를 위한, 활성화 응고 제ix 인자 및 응고 제x 인자와 결합하는 이중 특이성 항체와 혈액 응고 제x 인자의 병용 Pending KR20250174932A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2023-074020 2023-04-28
JP2023074020 2023-04-28
PCT/JP2024/016461 WO2024225440A1 (ja) 2023-04-28 2024-04-26 血友病ａを有する対象の処置のための、活性化凝固第ｉｘ因子及び凝固第ｘ因子と結合する二重特異性抗体と血液凝固第ｘ因子の併用

Publications (1)

Publication Number Publication Date
KR20250174932A true KR20250174932A (ko) 2025-12-15

Family

ID=93256843

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257037065A Pending KR20250174932A (ko) 2023-04-28 2024-04-26 혈우병 a를 가지는 대상의 처치를 위한, 활성화 응고 제ix 인자 및 응고 제x 인자와 결합하는 이중 특이성 항체와 혈액 응고 제x 인자의 병용

Country Status (6)

Country Link
EP (1) EP4702987A1 (https=)
JP (1) JPWO2024225440A1 (https=)
KR (1) KR20250174932A (https=)
CN (1) CN121013727A (https=)
AU (1) AU2024263657A1 (https=)
WO (1) WO2024225440A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6013915B2 (ja) 2010-11-17 2016-10-25 中外製薬株式会社 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子
JP6698102B2 (ja) 2015-04-17 2020-05-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 凝固因子と多重特異的抗体を用いた併用療法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6013915B2 (ja) 2010-11-17 2016-10-25 中外製薬株式会社 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子
JP6698102B2 (ja) 2015-04-17 2020-05-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 凝固因子と多重特異的抗体を用いた併用療法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ferriere S, et al. Blood. (2020) 136:740-8
Laura Downey, et al. Anesth Analg. (2017;125:1431-1436)
Yuto Nakajima, et al. Haemophilia (2022;28:e149-e152)

Also Published As

Publication number Publication date
JPWO2024225440A1 (https=) 2024-10-31
WO2024225440A1 (ja) 2024-10-31
AU2024263657A1 (en) 2025-11-13
CN121013727A (zh) 2025-11-25
EP4702987A1 (en) 2026-03-04

Similar Documents

Publication Publication Date Title
US9090697B2 (en) Methods for treating bleeding disorders
US20220089778A1 (en) Coagulation factor binding proteins and uses thereof
Mancuso et al. Benefits and risks of non‐factor therapies: Redefining haemophilia treatment goals in the era of new technologies
JP6216954B2 (ja) トロンビン結合性抗体分子及びその使用
Schultz et al. The effect of emicizumab and bypassing agents in patients with hemophilia–an in vitro study
JP7319721B2 (ja) 抗凝固因子ＸＩ活性型因子ＸＩａ抗体並びにその調製方法及び使用
Peyvandi et al. Exploring nonreplacement therapies’ impact on hemophilia and other rare bleeding disorders
US10676539B2 (en) Tissue plasminogen activator antibodies and methods of use
JP7535849B2 (ja) 出血治療のための止血促進タンパク質
CN106413744B (zh) 用于在出血性疾病治疗中改善止血的人凝血酶原和活化的因子x的组合物
KR20250174932A (ko) 혈우병 a를 가지는 대상의 처치를 위한, 활성화 응고 제ix 인자 및 응고 제x 인자와 결합하는 이중 특이성 항체와 혈액 응고 제x 인자의 병용
Schuepbach et al. Lepirudin therapy for thrombotic complications in congenital afibrinogenaemia
JP6704420B2 (ja) フォンヴィレブランド因子の半減期を改善するための化合物
US20190169307A1 (en) Glycoprotein v inhibitors for use as coagulants
WO2025192741A1 (ja) 活性化血液凝固第ｖｉｉ因子及び血液凝固第ｘ因子を含む医薬組成物
SHIMA Studies on factor VIII toward a new therapeutic for hemophilia A
Bilgimol Chumappumkal et al. Traumatic bleeding and mortality in mice are intensified by iron deficiency anemia and can be rescued with tranexamic acid
Sim Protein S in Coagulation and Inflammation
US20170042981A1 (en) Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor
Osuna et al. Augmented emicizumab-driven coagulation potential in hemophilia A state by in vitro and in vivo supplementation of combined factors IX and X
KR20240099304A (ko) 인자 xi a2 도메인 결합 항체 및 이의 사용 방법
Woods et al. Coagulation factor concentrates for inherited bleeding disorders
JP2009502849A (ja) 血栓症及び癌の治療、及び／又は予防のためのａｃｒｐ３０の使用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)